<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1410">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341116</url>
  </required_header>
  <id_info>
    <org_study_id>TJ003234COV201</org_study_id>
    <nct_id>NCT04341116</nct_id>
  </id_info>
  <brief_title>Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)</brief_title>
  <official_title>A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I-Mab Biopharma Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I-Mab Biopharma Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multi-center trial to evaluate the
      safety and efficacy of TJ003234 administered as an intravenous (IV) infusion in subjects with
      severe COVID-19 under supportive care, and to assess the effect of TJ003234 on the levels of
      cytokines.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion (%) of subjects experiencing deterioration in clinical status</measure>
    <time_frame>Changes from baseline on Day 14</time_frame>
    <description>8-category ordinal scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>Up to 30 days after drug administration</time_frame>
    <description>Per CTCAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion (%) of subjects experiencing deterioration in clinical status</measure>
    <time_frame>Changes from baseline on Day 7 and Day 30</time_frame>
    <description>8-category ordinal scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical status</measure>
    <time_frame>On Day 7, Day 14 and Day 30</time_frame>
    <description>8-category ordinal scale: 8, Death; 7, ventilation in addition to extracorporeal membrane oxygen (ECMO), continuous renal replacement therapy (CRRT) or pressors; 6, Intubation and mechanical ventilation; 5, non-invasive mechanical ventilation (NIV) or high-flow oxygen; 4,Oxygen by mask or nasal prongs; 3, Hospitalization without oxygen supplementation; 2, Limitation of activities, discharge from hospital; and 1, No limitation of activities, discharge from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in clinical status</measure>
    <time_frame>On Day 7, Day 14 and Day 30</time_frame>
    <description>8-category ordinal scale: 8, Death; 7, ventilation in addition to extracorporeal membrane oxygen (ECMO), continuous renal replacement therapy (CRRT) or pressors; 6, Intubation and mechanical ventilation; 5, non-invasive mechanical ventilation (NIV) or high-flow oxygen; 4,Oxygen by mask or nasal prongs; 3, Hospitalization without oxygen supplementation; 2, Limitation of activities, discharge from hospital; and 1, No limitation of activities, discharge from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) score</measure>
    <time_frame>On Day 7 and Day 14</time_frame>
    <description>The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems. A higher score predicts a worse clinical outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PaO2/ FiO2</measure>
    <time_frame>On Day 7 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of time to normalization of oxygen saturation</measure>
    <time_frame>Up to 30 days after drug administration</time_frame>
    <description>Defined as SpO2≥94% sustained minimum 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in percentage of subjects requiring mechanical ventilation</measure>
    <time_frame>On Day 7 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Glucocorticoid use</measure>
    <time_frame>On Day 7 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate from any cause</measure>
    <time_frame>Up to 30 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>Up to 30 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in D-dimer</measure>
    <time_frame>On Day 7 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of TJ003234</measure>
    <time_frame>Day 1 predose, Day 1 End of Infusion, Day 7 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and titer of anti-drug antibodies (ADA)</measure>
    <time_frame>Day 1 predose, Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Coronavirus Disease 2019 COVID-19</condition>
  <arm_group>
    <arm_group_label>TJ003234 3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TJ003234 6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJ003234</intervention_name>
    <description>patients receive a single infusion</description>
    <arm_group_label>TJ003234 3 mg/kg</arm_group_label>
    <arm_group_label>TJ003234 6 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>patients receive a single infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 years or older (including 18 years); male or female

          -  Laboratory-confirmed SARS-CoV-2 or COVID-19 infection as determined by polymerase
             chain reaction (PCR) or other commercial or public health assay.

          -  Bilateral lung infection confirmed by imaging.

          -  Hospitalized patients ≥60 years old with underlying medical comorbidities OR Severe
             disease that meets one of the following conditions: (i) At rest, finger blood oxygen
             saturation ≤ 93% or PaO2/FiO2 ≤ 300 mmHg; OR (ii) Requiring non-invasive or invasive
             mechanical ventilation.

        Exclusion Criteria:

          -  Any previous and/or current clinically significant disease or condition that has not
             been stable within 3 months prior to enrollment, or acute illness, planned medical/
             surgical procedure, or any trauma that occurred within 2 weeks prior to enrollment.

          -  Chronic obstructive pulmonary disease (COPD) patients requiring inhaled
             corticosteroid, long-acting beta-adrenergic agonists, long-acting anticholinergics, or
             long-term oxygen therapy.

          -  Pulmonary interstitial disease, pulmonary alveolar proteinosis, and pulmonary
             granulomatosis.

          -  Cardiovascular event in the 3 months prior to study drug administration: acute
             myocardial infarction or unstable angina pectoris, severe arrhythmia (multiple sources
             of frequent ventricular premature beat, ventricular tachycardia and ventricular
             fibrillation); New York Heart Association Classification (NYHA): Class III-Class IV.

          -  Blood system disorders or routine blood analysis test abnormalities: Hemoglobin &lt; 8
             g/dL; Absolute neutrophil count (ANC) &lt;1500 × 109/L; Platelets &lt; 50 × 109/L.

          -  Dependence on glucocorticoid treatment equivalent to methylprednisolone 2 mg/kg/ day
             or more or long-term use of anti-rejection or immunomodulatory drugs.

          -  Subjects that require ECMO.

          -  Pregnant or breastfeeding females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire Xu, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>I-Mab Biopharma US Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Site Head</last_name>
    <phone>240-767-6981</phone>
    <email>US.Info@I-MabBiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maximiliano Menna</last_name>
      <phone>202-444-0371</phone>
      <email>mpm229@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Princy Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The GW Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>msiegel@mfa.gwu.edu</email>
    </contact>
    <investigator>
      <last_name>Marc Siegel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OSF Healthcare Saint Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>skwynn@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>chage@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Chadi A. Hage, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medpharmics, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>andreajeanfreau@medpharmics.com</email>
    </contact>
    <investigator>
      <last_name>Robert Jeanfreau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>idresearch@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Julia Garcia-Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilise Marrazzo</last_name>
      <email>IMarrazzo@ihv.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Rohit Talwani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>crsp@umc.edu</email>
    </contact>
    <investigator>
      <last_name>Gailen D. Marshall, Jr., MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandon Labadie</last_name>
      <phone>971-337-6316</phone>
      <email>labadie@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Marcel Curlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple Univeristy Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ngentile@temple.edu</email>
    </contact>
    <investigator>
      <last_name>Nina Gentile, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>dgotur@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Deepa Gotur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 4, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

